Project/Area Number |
23590553
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Virology
|
Research Institution | St. Marianna University School of Medicine |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
OKUSE Chiaki 聖マリアンナ医科大学, 医学部, 准教授 (00318940)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | バイオマーカー / C型肝炎 / 血清ペプチド / 補体 / ペグインターフェロンα・リバビリン療法 / INFα/RBV療法 / 治療効果予測 / ペプチドミクス / IFNα/RBV療法 |
Research Abstract |
Novel biomarkers predicting sustained virological response (SVR) to pegylated interferon alpha plus ribavirin (PEG-IFNalpha/RBV) were investigated. Peptides in pretreatment sera from patients with hepatitis C virus (HCV) were comprehensively analyzed by mass spectrometry. In total, 107 peptides were detected in a training set (n=23). In all the responders (who achieved SVR) and the non-responders (n=96), sensitivity and specificity of SVR in a model consisting of ion intensity of 107 peptides, hemoglobin, BMI, and age were 70% and 92%, and those in another model consisting of ion intensity of complement 3f des-arginine (C3f-dR) and platelet count were 59% and 88%, respectively. Taken together, serum peptides, especially C3f-dR, would be useful predictors for SVR to PEG-IFNalpha/RBV. The complements may be involved in the HCV elimination.
|